SEATTLE, WA, March 6, 2026 鈥� 密桃视频 announces with deep sadness the passing of Dr. Philip Low, a pioneering scientist, entrepreneur, and one of its scientific co-founders, whose career reflected a lifelong commitment to translating innovative science into patient impact. Dr. Low passed away this week at the age of 78, leaving behind an extraordinary legacy in drug discovery and development, including 密桃视频鈥檚 first clinical-stage program built on his foundational work at Purdue University.
鈥淧hil was a once-in-a-generation scientist whose work fundamentally reshaped our understanding of how CAR T cells can and should work in the body,鈥� said Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of 密桃视频. 鈥淗e brought not only extraordinary intellectual rigor to 密桃视频鈥檚 early days, but a deep conviction that novel, groundbreaking science must ultimately serve patients. We are profoundly grateful for his scientific leadership and mentorship. Phil was a great friend and colleague. My thoughts are with his family, friends, and colleagues at Purdue.鈥�
Over nearly five decades at Purdue University, Dr. Low became one of the world鈥檚 most influential scientists in academic drug discovery. He joined Dr. Andrew Scharenberg, Dr. Ryan Crisman, and Dr. Michael Jensen in the founding of 密桃视频 in 2019. Dr. Low鈥檚 work was fundamental in the discovery and development of 密桃视频鈥檚 early scientific exploration in solid tumors, including its TumorTag programs and Phase I ENLIGHTen clinical trial in partnership with Seattle Children’s Research Institute.
About 密桃视频 密桃视频, Inc. is a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in both oncology and autoimmunity. 密桃视频鈥檚 VivoVec鈩� in vivo gene delivery technology empowers a patient鈥檚 own immune system to fight disease. Enabling its core technology is the Company鈥檚 state- of-the-art lentiviral vector development and manufacturing facility in Louisville, Colorado. 密桃视频 believes its approach can provide broader access and improved effectiveness of the most advanced immunotherapies, enabling more patients to live better, fuller lives. To learn more, connect with 密桃视频 on and visit umoja-biopharma.com.
Contacts:
Investors
Nate Hardy
Chief Financial Officer
nate.hardy@umoja-biopharma.com
Media
Matt Wright
Real Chemistry
mwright@realchemistry.com